Literature DB >> 18990156

Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?

Arun Sahai1, Philippa Sangster, Vinay Kalsi, Mohammad S Khan, Clare J Fowler, Prokar Dasgupta.   

Abstract

OBJECTIVE: To assess whether incomplete bladder emptying and the need for clean intermittent self-catheterization (CISC) is predictable, by analysing urodynamic and detrusor contractility variables in patients treated with botulinum toxin-A (BTX-A) for refractory idiopathic detrusor overactivity (IDO). PATIENTS AND METHODS: Sixty-seven patients (mean age 50.3) with IDO, from two centres, had bladder injections of 200 U BTX-A. Patients with difficulty in emptying their bladder and/or persistent overactive bladder symptoms, with postvoid residual volumes (PVR) of >150 mL after treatment were started on CISC. Urodynamics were conducted at baseline, 4 and 12-16 weeks after injection with BTX-A. Detrusor contractility was assessed using the projected isovolumetric pressure (PIP1) in women and bladder contractility index (BCI) in men.
RESULTS: There were improvements in the mean maximum cystometric capacity, bladder compliance and maximum detrusor pressures during filling cystometry after BTX-A injections. The PVR was significantly increased at 4 but not at 12 weeks. Nineteen patients required CISC and when compared with those not needing CISC their pretreatment maximum flow rate (15 vs 22 mL/s, P = 0.003), PIP1 (43 vs 58, P = 0.02) and BCI (113 vs 180, P = 0.001) were lower. Receiver operator characteristic curve analysis suggested that a PIP1 of < or =50 in women (sensitivity 0.83; specificity 0.70; area under the curve 0.822) and BCI < or =120 (sensitivity 0.7; specificity 0.79; area 0.879) might predict the need for CISC.
CONCLUSION: The maximum flow rate, PIP1 and BCI were significantly lower in patients who required CISC after BTX-A treatment than in those who did not. A PIP1 of < or =50 in women and a BCI of < or =120 might be predictive of a need for CISC in this setting, and might help when counselling patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990156     DOI: 10.1111/j.1464-410X.2008.08076.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

1.  Repeated botulinum toxin type A (Dysport) injections for women with intractable detrusor overactivity: a prospective outcome study.

Authors:  Lanka Abeywickrama; Angamuthu Arunkalaivanan; Monica Quinlan
Journal:  Int Urogynecol J       Date:  2013-10-17       Impact factor: 2.894

2.  Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.

Authors:  Jan Krhut; Peter Zvara
Journal:  Int Urol Nephrol       Date:  2010-06-20       Impact factor: 2.370

Review 3.  Novel biomarkers for overactive bladder.

Authors:  Rufus Cartwright; Iram Afshan; Alexandros Derpapas; Gopalan Vijaya; Vik Khullar
Journal:  Nat Rev Urol       Date:  2011-02-15       Impact factor: 14.432

4.  Intravesical botulinum toxin for lower urinary tract dysfunction.

Authors:  Marcus John Drake
Journal:  F1000 Med Rep       Date:  2010-01-27

5.  Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.

Authors:  David James Osborn; Melissa R Kaufman; Stephen Mock; Michael J Guan; Roger R Dmochowski; W Stuart Reynolds
Journal:  Neurourol Urodyn       Date:  2014-06-29       Impact factor: 2.696

6.  Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study.

Authors:  Gaetano De Rienzo; Paolo Minafra; Ester Iliano; Enrico Finazzi Agrò; Maurizio Serati; Alessandro Giammò; Francesco Paolo Bianchi; Elisabetta Costantini; Pasquale Ditonno
Journal:  Neurourol Urodyn       Date:  2021-10-19       Impact factor: 2.367

7.  Botulinum toxin-A for the treatment of overactive bladder: UK contributions.

Authors:  J H Seth; C Dowson; M S Khan; J N Panicker; C J Fowler; P Dasgupta; A Sahai
Journal:  J Clin Urol       Date:  2013-03

Review 8.  Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Possible Pathomechanisms and Practical Issues.

Authors:  Jia-Fong Jhang
Journal:  Toxins (Basel)       Date:  2019-11-04       Impact factor: 4.546

9.  Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.

Authors:  Osama Abdelwahab; Hammouda Sherif; Tark Soliman; Ihab Elbarky; Aly Eshazly
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.